-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Metastatic Melanoma Drug Details: Lenvatinib mesylate (Lenvima...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKX-019 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKX-019 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKX-019 in Mantle Cell Lymphoma Drug Details: NKX-019 is under...
-
New
Likelihood of Approval and Phase Transition Success Rate Model – MHB-036C in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-036C in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-036C in Non-Small Cell Lung Cancer Drug Details: MHB-036C...
-
Product Insights
NewNet Present Value Model: Altimmune Inc’s Pemvidutide
Empower your strategies with our Net Present Value Model: Altimmune Inc's Pemvidutide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Viridian Therapeutics Inc’s VRDN-001
Empower your strategies with our Net Present Value Model: Viridian Therapeutics Inc's VRDN-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Altimmune Inc
Altimmune Inc (Altimmune), is a a biopharmaceutical company. It focuses on developing liver disease and immune modulating therapies. The company’s pipeline products include ALT-801, a glucagon receptor to treat metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). Altimmune also offers nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy to patients chronically infected with the hepatitis B virus; nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores. In addition, its products find its...
-
Product Insights
NewNet Present Value Model: Iovance Biotherapeutics Inc’s LN-145
Empower your strategies with our Net Present Value Model: Iovance Biotherapeutics Inc's LN-145 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewZika Virus Infections – Drugs In Development, 2024
Empower your strategies with our Zika Virus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can also be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...
-
Product Insights
NewMalaria – Drugs In Development, 2024
Empower your strategies with our Malaria – Drugs In Development, 2024 report and make more profitable business decisions. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea, and vomiting. Treatment includes anti-malarial medicines....